{"nctId":"NCT04334148","briefTitle":"Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine","startDateStruct":{"date":"2020-04-22","type":"ACTUAL"},"conditions":["COVID-19"],"count":1360,"armGroups":[{"label":"Hydroxychloroquine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Hydroxychloroquine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo oral tablet"]}],"interventions":[{"name":"Hydroxychloroquine","otherNames":["Plaquenil"]},{"name":"Placebo oral tablet","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion:\n\n* Completed Informed Consent\n* Age ≥ 18 years old\n* Currently working in any environment in which there is a risk of exposure to patients with COVID-19 infections (\"healthcare worker\")\n\nExclusion Criteria:\n\n* Prior diagnosis of COVID-19 infection\n* Participation in another COVID-19 prophylaxis trial within 30 days of consent\n* Respiratory illness with new-onset fever (Temperature \\> 100°F) or ongoing cough or dyspnea within 14 days\n* Known allergy to HCQ or chloroquine\n* Congenital prolonged QT syndrome\n* Current or planned use of QT prolonging drugs (e.g. procainamide, disopyramide, mexiletine, flecainide, propafenone, amiodarone, sotalol, cimetidine, dronedarone, dofetilide, levofloxacin, ciprofloxacin, moxifloxacin) and other contraindicated medications\n* End stage renal disease\n* Pre-existing retinopathy\n* Current or planned use of Hydroxychloroquine (study drug) for any indication\n\nCurrent or planned use of the following for treatment or prevention of COVID-19 infection:\n\n* Chloroquine\n* Azithromycin\n\n  * Known cirrhosis or severe liver disease\n  * History of severe skin reactions such as Steven-Johnson syndrome, toxic epidermal necrolysis\n  * History of psoriasis or porphyria\n  * Ventricular arrhythmias requiring medical treatment\n  * Severe coronary artery disease or heart failure/cardiomyopathy with ongoing symptoms\n  * Current or planned use of use of anti-seizure drugs\n  * History of Glucose-6-phosphate dehydrogenase deficiency","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Clinical Infection With COVID-19 Infection","description":"This measure was a combination of confirmed infection and suspected infection. Confirmed clinical infection was defined as new-onset of fever or cough or dyspnea AND confirmed COVID-19 positive test result via local PCRI testing. Suspected infection was defined as new-onset fever or cough or dyspnea without local PCR testing due to local restrictions and/or testing policies.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With COVID-19 Viral Shedding","description":"Number of participants with COVID-19 infection shedding via Covance swab PCR testing","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events (SAEs) or Hydroxychloroquine-Associated Events of Special Interest (EOSIs)","description":"Safety and Tolerability as determined by subject reported serious adverse events (SAEs) and hydroxychloroquine-associated events of special interest. EOSIs include: arrhythmias (ventricular), hepatic failure, bone marrow failure, aplastic anemia, prolonged QT interval, angioedema, dermatitis exfoliative, acute generalized exanthematous pustulosis, psychosis, suicidal ideation, seizure, methemoglobinemia.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":683},"commonTop":[]}}}